Positive_JJ
and_CC
negative_JJ
regulation_NN
of_IN
the_DT
composite_JJ
octamer_NN
motif_NN
of_IN
the_DT
interleukin_NN
2_CD
enhancer_NN
by_IN
AP-1_NN
,_,
Oct-2_NN
,_,
and_CC
retinoic_JJ
acid_NN
receptor_NN
._.

The_DT
differentiating_VBG
agent_NN
retinoic_JJ
acid_NN
-LRB-_-LRB-
RA_NN
-RRB-_-RRB-
has_VBZ
been_VBN
previously_RB
reported_VBN
to_TO
interfere_VB
with_IN
12-O-tetradecanoyl-phorbol-13-acetate_NN
-LRB-_-LRB-
TPA_NN
-RRB-_-RRB-
\/_CC
Ca_NN
-LRB-_-LRB-
2_CD
+_NN
-RRB-_-RRB-
-_:
induced_JJ
signals_NNS
for_IN
the_DT
regulation_NN
of_IN
the_DT
-96_CD
to_TO
-66_CD
-_:
bp_NN
octamer_NN
motif_NN
found_VBN
in_IN
the_DT
enhancer_NN
for_IN
the_DT
interleukin_NN
-LRB-_-LRB-
IL_NN
-RRB-_-RRB-
-2_CD
gene_NN
,_,
which_WDT
encodes_VBZ
a_DT
major_JJ
T_NN
lymphocyte_NN
growth_NN
factor_NN
._.

The_DT
IL-2_NN
octamer_NN
motif_NN
is_VBZ
a_DT
composite_JJ
cis-element_NN
which_WDT
binds_VBZ
Oct-1_NN
and_CC
Oct-2_NN
as_RB
well_RB
as_IN
a_DT
TPA\/Ca_NN
-LRB-_-LRB-
2_CD
+_NN
-RRB-_-RRB-
-_:
inducible_JJ
nuclear_JJ
factor_NN
,_,
previously_RB
termed_VBN
octamer-associated_JJ
protein_NN
-LRB-_-LRB-
OAP40_NN
-RRB-_-RRB-
._.

We_PRP
show_VBP
here_RB
that_IN
Oct-2_NN
,_,
despite_IN
the_DT
presence_NN
of_IN
an_DT
active_JJ
transcriptional_JJ
activation_NN
domain_NN
,_,
requires_VBZ
TPA\/Ca_NN
-LRB-_-LRB-
2_CD
+_NN
-RRB-_-RRB-
-_:
induced_JJ
signals_NNS
to_TO
strongly_RB
transactivate_VB
the_DT
IL-2_NN
octamer_NN
motif_NN
in_IN
Jurkat_NN
T_NN
cells_NNS
._.

This_DT
Oct-2-dependent_JJ
transactivation_NN
is_VBZ
inhibited_VBN
by_IN
RA_NN
._.

The_DT
presence_NN
of_IN
an_DT
intact_JJ
COOH-terminal_JJ
domain_NN
of_IN
Oct-2_NN
contributes_VBZ
to_TO
both_CC
TPA\/Ca_NN
-LRB-_-LRB-
2_CD
+_NN
-RRB-_-RRB-
-_:
induced_JJ
transactivation_NN
and_CC
the_DT
RA-mediated_JJ
repression_NN
._.

We_PRP
also_RB
show_VBP
that_IN
both_CC
Fos_NN
and_CC
Jun_NN
components_NNS
of_IN
the_DT
AP-1_NN
factors_NNS
participate_VBP
in_IN
the_DT
OAP40_NN
complex_NN
._.

Furthermore_RB
,_,
transfected_VBN
c-jun_NN
,_,
jun-B_NN
,_,
jun-D_NN
,_,
c-fos_NN
,_,
or_CC
Fos-B_NN
expression_NN
vectors_NNS
partially_RB
substitute_VBP
for_IN
TPA_NN
and_CC
Ca2_NNP
+_NNP
and_CC
cooperate_VBP
with_IN
Oct-2_NN
for_IN
the_DT
transactivation_NN
of_IN
the_DT
combined_JJ
OAP\/octamer_NN
cis-element_NN
._.

Mutations_NNS
of_IN
the_DT
genuine_JJ
octamer-binding_JJ
site_NN
abrogate_VBP
both_CC
the_DT
binding_NN
of_IN
Oct-1_NN
and_CC
Oct-2_NN
and_CC
the_DT
TPA\/Ca_NN
-LRB-_-LRB-
2_CD
+_NN
-RRB-_-RRB-
-_:
induced_VBN
transactivation_NN
of_IN
the_DT
OAP\/octamer_NN
motif_NN
._.

OAP_NN
confers_VBZ
to_TO
Oct-2_NN
responsivity_NN
to_TO
both_CC
TPA\/Ca2_NNP
+_NNP
and_CC
RA_NN
,_,
since_IN
specific_JJ
mutations_NNS
of_IN
the_DT
AP-1_NN
\/_:
OAP-binding_NN
site_NN
significantly_RB
reduce_VBP
the_DT
transactivation_NN
by_IN
Oct-2_NN
in_IN
response_NN
to_TO
TPA_NN
and_CC
Ca2_NNP
+_NNP
and_CC
abolish_VBP
the_DT
inhibition_NN
by_IN
RA_NN
._.

Furthermore_RB
,_,
retinoic_JJ
acid_NN
receptor_NN
-LRB-_-LRB-
RAR_NN
-RRB-_-RRB-
alpha_NN
is_VBZ
able_JJ
to_TO
inhibit_VB
in_FW
vitro_FW
the_DT
formation_NN
of_IN
the_DT
complex_NN
between_IN
the_DT
nuclear_JJ
AP-1_NN
\/_:
OAP_NN
and_CC
its_PRP$
specific_JJ
binding_VBG
site_NN
,_,
resulting_VBG
in_IN
the_DT
interference_NN
with_IN
Oct-2-dependent_JJ
cis-regulatory_JJ
function_NN
of_IN
this_DT
AP-1_NN
element_NN
._.

Therefore_RB
,_,
we_PRP
propose_VBP
that_IN
the_DT
TPA\/calcium-activated_JJ
AP-1_NN
\/_:
OAP_NN
element_NN
is_VBZ
the_DT
main_JJ
target_NN
of_IN
positive_JJ
or_CC
negative_JJ
regulatory_JJ
signals_NNS
influencing_VBG
the_DT
IL-2_NN
octamer_NN
motif_NN
,_,
through_IN
synergism_NN
with_IN
Oct-2_NN
and_CC
antagonism_NN
by_IN
RAR_NN
._.

